CareDx, Inc (CDNA) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 13 analysts3.1% Below Target
CDNA trades 3.1% below Wall Street's consensus target of $27.00.
Current Price$26.18
Average Target$27.00
Target
Current
Low$26.00
Median$27.00
High$28.00
Analyst Target Range
Forward P/E28.0x
(Growth Premium)
PEG Ratio—
Implied Growth+705.7%
(High Growth)
Analyst Spread7.4%
(High Agreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes CDNA achieves its forward estimates and maintains a stable P/E multiple of 28.0x. This scenario reflects the blended consensus of 13 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
CDNA Price Target Analysis
Updated June 21, 2026As of June 21, 2026, CareDx, Inc (CDNA) has a Wall Street consensus price target of $27.00, based on estimates from 13 covering analysts. With the stock currently trading at $26.18, this represents a potential upside of +3.1%. The company has a market capitalization of $1.35B.
Analyst price targets range from a low of $26.00 to a high of $28.00, representing a 7% spread in expectations. The median target of $27.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 10 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CDNA trades at a trailing P/E of -65.5x and forward P/E of 28.0x. Analysts expect EPS to grow +705.7% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+11.2%
Industry Consensus
Avg Forward P/E
136.5x
(High Premium)
Peers with Coverage
9 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NTRANatera, Inc. | $33.1B | $231.41 | $259.88 | +12.3% | Buy | — | 27 |
 EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
 PACBPacific Biosciences of California, Inc. | $435M | $1.40 | $1.00 | -28.6% | Buy | — | 18 |
 ILMNIllumina, Inc. | $24.6B | $161.93 | $151.40 | -6.5% | Buy | 31.0x | 50 |
 TXMDTherapeuticsMD, Inc. | $23M | $1.95 | — | — | — | — | — |
 FLGTFulgent Genetics, Inc. | $535M | $18.00 | $15.00 | -16.7% | Buy | — | 9 |
 VCYTVeracyte, Inc. | $4.3B | $53.63 | $47.60 | -11.2% | Buy | 29.3x | 20 |
 PGNYProgyny, Inc. | $2.0B | $26.08 | $30.33 | +16.3% | Buy | 20.4x | 20 |
 CSTLCastle Biosciences, Inc. | $641M | $21.12 | $43.50 | +106.0% | Buy | — | 11 |
 TMOThermo Fisher Scientific Inc. | $172.7B | $464.61 | $599.70 | +29.1% | Buy | 18.7x | 42 |
CDNA — Frequently Asked Questions
Quick answers to the most common questions about buying CDNA stock.
What is the CDNA stock price target for 2026?
The consensus price target for CDNA is $27, close to the current price of $26.18 (3.1% implied move). Based on 13 analyst estimates, the stock appears fairly valued near current levels.
Is CDNA a buy, sell, or hold?
CDNA has a consensus rating of "Buy" based on 13 Wall Street analysts. The rating breakdown is predominantly bullish, with 10 Buy/Strong Buy ratings. The consensus 12-month price target of $27 implies 3.1% upside from current levels.
Is CDNA stock overvalued or undervalued?
CDNA trades at a forward P/E of 28.03x, representing a moderate valuation. With analysts targeting $27 (3.1% implied move), the stock appears close to fair value.
How high can CDNA stock go?
The most bullish Wall Street analyst has a price target of $28 for CDNA, while the most conservative target is $26. The consensus of $27 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover CDNA stock?
CDNA is moderately covered, with 13 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the CDNA stock forecast?
The 12-month CDNA stock forecast based on 13 Wall Street analysts shows a consensus price target of $27, with estimates ranging from $26 (bear case) to $28 (bull case). The median consensus rating is "Buy".
What is CDNA's forward P/E ratio?
CDNA trades at a forward P/E ratio of 28.0x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy CDNA stock?
CDNA appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $27 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do CDNA price targets vary so much?
CDNA analyst price targets range from $26 to $28, a 7% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $27 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare